Skip to main content
Amir Fathi, MD, Oncology, Boston, MA

Amir T Fathi MD

Oncology•Boston, MA

Hematologic Oncology

Associate Professor of Medicine, Harvard Medical School -- Director, Leukemia Program, Massachusetts General Hospital

Join to View Full Profile

  • 55 Fruit StBoston, MA 02114

  • Phone+1 617-724-1124

  • Fax+1 617-724-1126

Dr. Fathi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Fathi's Full ProfileAlready have an account?

Education & Training

  • Harvard School of Public Health
    Harvard School of Public HealthMasters, Epidemiology, 2012 - 2014
  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Mass General Brigham/Massachusetts General Hospital
    Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2004 - 2007
  • Yale School of Medicine
    Yale School of MedicineClass of 2004
  • Yale University
    Yale UniversityBS, 1996 - 2000

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2006 - 2026
  • MD State Medical License
    MD State Medical License 2007 - 2010
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
  • CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia  
    Areej El-Jawahri, Thomas W Leblanc, Selina M Luger, Bhavana Bhatnagar, Alison R Walker, Amir T Fathi, Andrew M Brunner, Gabriela S Hobbs, Jennifer S Temel, JAMA Oncology
  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
    Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
  • A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML  
    Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

  • Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
    Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myelo...
    Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
    Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • AML: Expert Guidance on Current Standards and New Directions in Patient Care 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Benefit of Azacitidine plus Venetoclax Confirmed in AML
    Benefit of Azacitidine plus Venetoclax Confirmed in AMLJanuary 8th, 2026
  • After 5 Decades, Is Standard AML Treatment for Young and Fit Patients About to Change?
    After 5 Decades, Is Standard AML Treatment for Young and Fit Patients About to Change?December 11th, 2025
  • Roswell Park Leukemia Expert Led ASH 2025 Studies Assessing 2 New Treatment Strategies for Advanced AML
    Roswell Park Leukemia Expert Led ASH 2025 Studies Assessing 2 New Treatment Strategies for Advanced AMLDecember 9th, 2025

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Amir Fathi, Dr. Amir Fathi, MD, Dr. A Fathi, Dr. Amir T Fathi